m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00751)
Target Name | hsa_circ_0004287 | ||||
---|---|---|---|---|---|
Gene Name | hsa_circ_0004287 |
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
hsa_circ_0004287
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | hsa_circ_0004287 was upregulated in peripheral blood mononuclear cells of both AD and psoriasis patients. hsa_circ_0004287 reduced the stability of its host gene metastasis associated lung adenocarcinoma transcript 1 (MALAT1) by competitively binding to IGF2BP3 with MALAT1 in an N6-methyladenosine (m6A)-dependent manner. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Atopic eczema | ICD-11: EA80 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Ubiquitin mediated proteolysis | hsa04120 | |||
Cell Process | Inflammation | |||
Proteasome pathway degradation | ||||
In-vitro Model | RAW 264.7 | Mouse leukemia | Mus musculus | CVCL_0493 |
In-vivo Model | IMQ-induced psoriatic model was constructed by applying 10 mg per ear 5% IMQ for 8 consecutive days, and 6 ug macrophage-specific control or hsa_circ_0004287 plasmid was topically applied every 2 days (5 mice per group per experiment). | |||
Atopic eczema [ICD-11: EA80]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | hsa_circ_0004287 was upregulated in peripheral blood mononuclear cells of both AD and psoriasis patients. hsa_circ_0004287 reduced the stability of its host gene metastasis associated lung adenocarcinoma transcript 1 (MALAT1) by competitively binding to IGF2BP3 with MALAT1 in an N6-methyladenosine (m6A)-dependent manner. | |||
Responsed Disease | Atopic eczema [ICD-11: EA80] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Ubiquitin mediated proteolysis | hsa04120 | |||
Cell Process | Inflammation | |||
Proteasome pathway degradation | ||||
In-vitro Model | RAW 264.7 | Mouse leukemia | Mus musculus | CVCL_0493 |
In-vivo Model | IMQ-induced psoriatic model was constructed by applying 10 mg per ear 5% IMQ for 8 consecutive days, and 6 ug macrophage-specific control or hsa_circ_0004287 plasmid was topically applied every 2 days (5 mice per group per experiment). | |||